Sofosbuvir/velpatasvir with tenofovir alafenamide efficacious for HCV, HBV co-infection

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

<button type="button" class="btn btn-primary" data-loading-text="Loading ” data-action=”subscribe”>
Subscribe

Added to email alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

Back to Healio

Key takeaways:

• High rates of sustained virologic response were achieved after 12 weeks of sofosbuvir/velpatasvir plus tenofovir alafenamide.
• Most patients did not experience significant adverse effects with treatment.

BOSTON — After 12 weeks of treatment with sofosbuvir/velpatasvir in combination with tenofovir alafenamide, patients with hepatitis C virus and hepatitis B virus co-infection demonstrated high rates of sustained virologic response.

Hongyu Chen

Moreover, patients did not experience reactivation of HBV DNA during the treatment period, according to data presented at The Liver Meeting.

Hongyu Chen, MD, from Peking University First Hospital in Beijing, and colleagues conducted a multicenter, prospective, single-arm, open-label clinical trial evaluating the safety and efficacy of sofosbuvir/velpatasvir combined with prophylactic use of tenofovir alafenamide among 60 Chinese patients with HCV and HBV co-infection.

Participants were divided into noncirrhotic (n = 47) and compensated cirrhotic (n = 13) groups and received tenofovir alafenamide for 7 months, from day 0 to week 28, and sofosbuvir/velpatasvir for 3 months, from week 4 to week 16.

 

Source: Hongyu C, et al. The efficacy and safety of 12-week SOF/VEL regimen combined with prophylactic use of TAF for treatment-naive genotype1-6 HCV/HBV co-infection adult patients with or without compensated cirrhosis in China: A multicenter, prospective, single-arm, open-label trial. Presented at: The Liver Meeting; Nov. 10-14, 2023; Boston (hybrid meeting).

The primary endpoint was SVR 12 weeks after discontinuation of sofosbuvir/velpatasvir treatment.

According to results, the overall SVR rate was 98.3% 12 weeks after discontinuation of therapy, with just one patient in the noncirrhotic group converting to HCV RNA positive.

At baseline, 28 patients were HBV DNA positive compared with two patients at week 28. Further, no HBV DNA reactivation was reported during treatment, according to results. Most patients did not experience significant adverse events.

“[Direct-acting antiviral] therapy using SOF/VEL has demonstrated remarkable efficacy and safety when treating patients co-infected with HBV and HCV,” Hongyu told Healio.

Published by: